Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Debu Tripathy, MD, MD Anderson Cancer Center

Advertisement

Articles by Debu Tripathy, MD, MD Anderson Cancer Center

Updated Data for Metastatic HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center
January 25th 2021
Advertisement

Latest Updated Articles

  • Prognostic Tools for Early-Stage HER2+ Breast Cancer
    Prognostic Tools for Early-Stage HER2+ Breast Cancer

    January 25th 2021

  • Current Treatment Landscape for HER2+ Breast Cancer
    Current Treatment Landscape for HER2+ Breast Cancer

    January 25th 2021

  • Updated Data for Metastatic HER2+ Breast Cancer
    Updated Data for Metastatic HER2+ Breast Cancer

    January 25th 2021



Advertisement
Advertisement

Trending on OncLive

1

Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

2

Five Under 5: Top Oncology Videos for the Week of 6/28

3

The OncFive: Top Oncology Articles for the Week of 6/28

4

Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera

5

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us